TF-2016-02

The management of malignant pleural effusions

Chairs: Nick Maskell and Giuseppe Cardillo

Malignant pleural effusions (MPE) are common, affecting more than 400,000 people in Europe each year. They are associated with a poor prognosis as their presence usually signifies advanced or metastatic disease.

Median survival ranges from 3 to 12 months, depending on the underlying tumour type. In 2010, the British Thoracic Society (BTS) produced guidelines on the investigation of unilateral pleural effusions and the management of MPE. However, many advances in the field of pleural disease have been made in the past 5 years. This task force therefore aims to develop a comprehensive and up-to-date summary of the literature relating to MPE.